Our mission at Sigilon Therapeutics is to develop improved treatments for chronic diseases using a novel type of therapeutic: implanted cells shielded by proprietary biomaterials from immune attack and the foreign body response (fibrosis). Treatments based on the Sigilon Therapeutics technology platform will act as responsive “living therapeutics” that can provide more natural control for diseases currently treated with intermittent injection or infusion.